Organizational, direct support, and general support maintenance repair parts and special tools list (including depot maintenance repair parts and special tools) for test set, radio, AN/GRM-114 (NSN 6625-01-108-6206).

"20 May 1983."

Operator, organizational, direct support, and general support maintenance manual : shop equipment guided missile system contact support set (CSS) AN/TSM-135A, 4935-01-114-3919 : TOW 2/Dragon Weapon System.

"May 1983."

Operator, organizational, direct and general support maintenance manual : heater, space, multi-fuel, with blower, 60,000 BTU/hr, (Hunter model UH-68[[D), FSN 4520-114-1055.

"June 1969."

Operator's and organizational maintenance manual : test set, radio data link, sound ranging, TS-3566/GRA-114 (NSN 5895-01-064-9740).

"30 July 1982."

Operator's and organizational maintenance manual : control, radio channel C-10931(P)/FRC (NSN 5820-01-114-1456).

"July 1982."

Price discrimination, the Robinson-Patman Act, and related matters : hearings before the Select Committee on Small Business, House of Representatives, Eighty-fourth Congress, first session, pursuant to H. Res. 114, a resolution creating A Select Committee to Conduct a Study and Investigation of the Problems of Small Business. October 31-November 17, 1955.

Mode of access: Internet.

Psalm no. 114; op.51, for 8 voices, chorus and orchestra. Psalm no. 98, op. 91, for 8 voices, chorus and orchestra.

Words in German.

Hs. Rothschild 4° 114 - Testament des Bernhard Juda Sichel und seiner Ehegattin Betty aus dem Jahr 1858 (Abschrift)

Vorbesitzer: Freiherrlich Carl von Rothschild'sche Bibliothek Frankfurt am Main; alte Signatur: Hs. in Quart 114

Seismic Wave Velocity as a Means of In-Place Density Measurement, HR-114, Final Report, Part 2 of 2

As noted in Part 1 of this report, the objective of the investigation was to apply principles of first-arrival seismic refraction to the problem of more quickly determining in-place dry density in highway materials. Part 2 of the report, contained herein, presents the results of both additional laboratory development of test techniques, plus extensive field test data.

Resolución 114 del 21 de julio de 2009: ¿Cuál es la verificación que hace la Cámara de Comercio respecto de las providencias judiciales? ¿Cómo se evalúa la inscripción de un embargo cuando en el establecimiento figuran varios propietarios?

Servicios registrales

Resolución 114 del 30 de agosto de 2013: Por la cual se acepta un desistimiento

Servicios registrales

Cardiac Magnetic Resonance Assessment Of Interstitial Myocardial Fibrosis And Cardiomyocyte Hypertrophy In Hypertensive Mice Treated With Spironolactone.

Nearly 50% of patients with heart failure (HF) have preserved LV ejection fraction, with interstitial fibrosis and cardiomyocyte hypertrophy as early manifestations of pressure overload. However, methods to assess both tissue characteristics dynamically and noninvasively with therapy are lacking. We measured the effects of mineralocorticoid receptor blockade on tissue phenotypes in LV pressure overload using cardiac magnetic resonance (CMR). Mice were randomized to l-nitro-ω-methyl ester (l-NAME, 3 mg/mL in water; n=22), or l-NAME with spironolactone (50 mg/kg/day in subcutaneous pellets; n=21). Myocardial extracellular volume (ECV; marker of diffuse interstitial fibrosis) and the intracellular lifetime of water (τic; marker of cardiomyocyte hypertrophy) were determined by CMR T1 imaging at baseline and after 7 weeks of therapy alongside histological assessments. Administration of l-NAME induced hypertensive heart disease in mice, with increases in mean arterial pressure, LV mass, ECV, and τic compared with placebo-treated controls, while LV ejection fraction was preserved (>50%). In comparison, animals receiving both spironolactone and l-NAME (l-NAME+S) showed less concentric remodeling, and a lower myocardial ECV and τic, indicating decreased interstitial fibrosis and cardiomyocyte hypertrophy (ECV: 0.43 ± 0.09 for l-NAME versus 0.25 ± 0.03 for l-NAME+S, P<0.001; τic: 0.42 ± 0.11 for l-NAME groups versus 0.12 ± 0.05 for l-NAME+S group). Mice treated with a combination of l-NAME and spironolactone were similar to placebo-treated controls at 7 weeks. Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in hypertensive heart disease. CMR can phenotype myocardial tissue remodeling in pressure-overload, furthering our understanding of HF progression.